Abstract Number: 2238 • ACR Convergence 2023
Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study
Background/Purpose: Psoriatic arthritis (PsA) has been associated with an increased risk of cardiovascular (CV) disease, likely due to accelerated atherosclerosis secondary to chronic inflammation.1 As…Abstract Number: 2333 • ACR Convergence 2023
Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…Abstract Number: 2318 • ACR Convergence 2023
The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study
Background/Purpose: Childhood-onset systemic lupus erythematosus patients < 18 years (cSLE) are at risk for reduced bone mineral density (BMD) due to disease activity and chronic…Abstract Number: 2242 • ACR Convergence 2023
Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
Background/Purpose: Psoriatic arthritis (PsA) is a chronic and progressive disease characterized by high rates of early joint erosions, which have been associated with impaired quality…Abstract Number: 2349 • ACR Convergence 2023
Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Background/Purpose: Toll-like receptor (TLR)7 is a pattern recognition receptor whose ligands include nucleic acids and whose gain-of-function mutations have been reported to result insystemic lupus…Abstract Number: 2348 • ACR Convergence 2023
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Background/Purpose: BEL-treated patients (pts) in clinical trials and long-term extension (LTE) studies1-7 experienced comparable incidence of infections versus those treated with standard therapy (ST) alone…Abstract Number: 2344 • ACR Convergence 2023
Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
Background/Purpose: The past decade has witnessed the innovation of several biologics in the treatment of systemic lupus erythematosus (SLE), most of which target B cells,…Abstract Number: 2241 • ACR Convergence 2023
Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Background/Purpose: Patients (pts) with psoriasis (PsO) or PsA are at increased risk for developing gout; and hyperuricemia (HU) prevalence is higher in PsO/PsA pts than…Abstract Number: 2343 • ACR Convergence 2023
Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by multi-systemic involvement and difficult-to-predict disease flares. Hydroxychloroquine (HCQ) has long been recognized as…Abstract Number: 2325 • ACR Convergence 2023
Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases
Background/Purpose: Antinuclear antibodies (ANAs) are a hallmark of systemic lupus erythematosus (SLE) and also a marker of subclinical autoimmunity. While a seminal study using the…Abstract Number: 2248 • ACR Convergence 2023
Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
Background/Purpose: In Psoriatic arthritis (PsA), patients who fail to respond to biologics and targeted synthetic therapies (ts/bDMARDs), switching to another ts/bDMARD should be considered. Failure…Abstract Number: 2252 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study
Background/Purpose: PsA is a chronic disease affecting multiple domains; however, patients (pts) can experience loss of response with long-term therapy.1 Therefore, maintaining long-term treatment responses…Abstract Number: 2328 • ACR Convergence 2023
Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in the US, EU, and other countries for treatment of adults…Abstract Number: 2335 • ACR Convergence 2023
Defining a Basket Population for ANA+ Arthritis Trials
Background/Purpose: Musculoskeletal (MSK) manifestations are common in systemic lupus erythematosus (SLE) and other ANA-associated rheumatic musculoskeletal diseases (ANA-RMDs). Presently clinical trials recruit patients from individual…Abstract Number: 2356 • ACR Convergence 2023
A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by inflammation and fibrosis. Treatment with mycophenolate mofetil (MMF), an inhibitor of lymphocyte…
- « Previous Page
- 1
- …
- 346
- 347
- 348
- 349
- 350
- …
- 2425
- Next Page »